April 2010
Pharmaceutical Representative;Apr2010, Vol. 40 Issue 4, p24
The article offers news briefs on the pharmaceutical community in the U.S. Representatives from Shire's ADHD Business Unit's Northeast Zone are promoted to senior professional sales representatives including Daniel Couture, Julia LeTarte and Danielle Zelenak. Dierdre Connelly of GSK was awarded Women of the Year for 2010 by the Healthcare Businesswomen's Association. OSI Pharmaceuticals Inc. has chosen Veeva Systems as the SaaS customer relationship management application for its sales team.


Related Articles

  • OSI dedicates plant.  // Chemical Market Reporter;11/24/97, Vol. 252 Issue 21, p33 

    Reports on OSI Pharmaceuticals Inc.'s dedication of an expanded medicinal, combinatorial and pharmaceutical chemistry facilities of its Aston molecules operation in Birmingham, England.

  • OSI operating revenues improve.  // Chemical Market Reporter;08/24/98, Vol. 254 Issue 8, p17 

    Reports on the improvement in OSI Pharmaceuticals Inc.'s financial performance for the period ended June 20, 1998. Net losses posted; Operating revenues; Increased collaborative program revenues associated with expansion of co-venture with Pfizer Inc.

  • SWOT Analysis.  // OSI Pharmaceuticals SWOT Analysis;Aug2009, p1 

    A company profile of Melville, New York-based OSI Pharmaceuticals Inc., which is a biotechnology company focused on drugs for oncology, diabetes and obesity, is presented. An overview of the company's operations and financial performance is given, along with key facts including contact...

  • OSI in Phase II on 2nd cancer drug; partner deal close? Solnik, Claude // Long Island Business News (7/1993 to 5/2009);12/22/2000, Vol. 47 Issue 51, p5A 

    Reports on the anti-cancer drug being developed by OSI Pharmaceuticals and the possible deal for the test of another drug developed by the company and Pfizer. Phase II clinical trials of OSI-774; Search of OSI for a partner in the development and distribution of the drug; Companies interested...

  • WORLD News & Analysis. Gopal, Kevin // Pharmaceutical Executive;Apr2001, Vol. 21 Issue 4, p32 

    Presents news on the pharmaceutical industry as of April 2001. Changes in the trade policies on health care affecting the industry; Number of pharmaceutical firms that submitted proposals to develop OSI-774, a compound for cancer treatment of OSI Pharmaceuticals; Growth in United States sales...

  • Stocks report.  // Long Island Business News (7/1993 to 5/2009);10/21/2005, Vol. 52 Issue 44, p8A 

    Reports on the condition of the shares of OSI Pharmaceuticals Inc. after the company was downgraded by Bear Stearns in the U.S.

  • Relocation. Solnik, Claude // Long Island Business News (7/1993 to 5/2009);5/26/2006, Vol. 53 Issue 22, p1B 

    The article discusses the OSI Pharmaceuticals' whirlwind tour in Long Island, New York. The anti-drug Tarceva manufacturer was provided with the information about the schools, shopping and demographics by the Coach Realtors during the tour. The group also obtained a glimpse of high ticket real...

  • New molecular entities.  // Formulary;Dec2004, Vol. 39 Issue 12, p568 

    Reports on the approval of Erlotinib manufactured by Genentech Inc. and OSI Pharmaceuticals Inc. for the treatment of patients with locally advanced or metastatic non-small cell lung cancer. Efficacy of the drug; Safety of the therapeutics; Recommended daily dosing.

  • OSI Pharmaceuticals working on skin drug.  // Long Island Business News (7/1993 to 5/2009);06/18/99, Vol. 46 Issue 25, p5B 

    Reports on OSI Pharmaceuticals and partners Pfizer Inc. and New York University's expansion of their collaboration with Anaderm Research Corp. in drug research and development. Anaderm's work in the area of cosmetic pharmaceuticals; Roles of each firm in the expanded program.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics